Additionally, survival analysis was conducted on tumor samples regarding KRAS mRNA expression, and no statistically significant differences were observed between the tumor samples and healthy tissue samples (C) (COAD; OS: HR = 0.9, p = 0.67; DFS: HR = 1.2, p = 0.53), (READ; OS: HR = 0.76, p = 0.58; DFS: HR = 0.67, p = 0.4) (Figure 3). This evidence concerns the gene KRAS and neoplasm.